Vidarbha News

Waldenstrom Macroglobulinemia Market Size and Share, Leading Companies, Emerging Therapies, and Epidemiology Forecast

 Breaking News
  • No posts were found

Waldenstrom Macroglobulinemia Market Size and Share, Leading Companies, Emerging Therapies, and Epidemiology Forecast

June 07
19:17 2021
Waldenstrom Macroglobulinemia Market Size and Share, Leading Companies, Emerging Therapies, and Epidemiology Forecast

Delveinsight Business Research LLP

DelveInsight’s “Waldenstrom Macroglobulinemia Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Waldenstrom Macroglobulinemia Market Size and Share in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

International Waldenstrom’s Macroglobulinemia Foundation (IWMF) has defined Waldenstrom’s macroglobulinemia (WM) as lymphoma or cancer of the lymphatic system. It occurs in white blood cells called a B-lymphocyte or B-cell, which normally matures into a plasma cell that manufactures immunoglobulin to help the body fight infection. WM cells have characteristics of both B-lymphocytes and plasma cells and hence classified as a type of non-Hodgkin’s lymphoma called lymphoplasmacytic lymphoma (LPL).

WM has an overall incidence of 1 out of 260,000 persons/year in the USA and a prevalence estimate of about 1 out of 102,220 in Europe. There are few cases of WM in younger people, but the chance of developing this disease goes up as people get older up to mid-60s. According to the American Society of Hematology, 2007, the overall incidence of Waldenstrom’s Macroglobulinemia was higher in males than females.WM is almost twice as common in men as it is in women.

Get FREE sample copy at:

The Waldenstrom Macroglobulinemia Market Research Report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted Waldenstrom Macroglobulinemia market Size from 2017 to 2030 segmented by seven major markets. 

The report provides a detailed current Waldenstrom Macroglobulinemia treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Waldenstrom Macroglobulinemia Market

Waldenstrom Macroglobulinemia Market Key Facts

  • The total prevalent cases of Waldenstrom’s Macroglobulinemia were 32,852 in the 7MM in 2017, which is expected to grow during the forecast period.

  • Similarly, the 7MM incident population was estimated to be 3817 cases in 2017.

  • As per the DelveInsight analysis, 8247 males and 4123 females were suffering from Waldenstrom’s Macroglobulinemia in 2017 in the US.

  • In EU5, the highest incident cases were reported to be in Germany followed by France and United Kingdom whereas the lowest incident rates were reported in Spain during the period.

Key Benefits of Waldenstrom Macroglobulinemia Market Report

  • Waldenstrom Macroglobulinemia market report provides an in-depth analysis of Waldenstrom Macroglobulinemia Market Size, Share, Trend, and Epidemiology Forecast till 2030 in the seven major markets (i.e. the United States, EU5 (Germany, Italy, Spain, France, and the UK) and Japan.

  • The report will help in developing business strategies by understanding the Waldenstrom Macroglobulinemia Market Trends, recent developments, key players, and future market competition that will shape and drive the market growth in the upcoming years.

  • The market report covers the Waldenstrom Macroglobulinemia current treatment practices, emerging drugs, market share of the individual therapies in the seven major markets.

  • The report provides a detailed assessment of the Waldenstrom Macroglobulinemia market in terms of market drivers & barriers, unmet needs, market opportunities, patient population, detailed comparative analysis of pipeline products including clinical and non-clinical stage products, and other factors. 

Waldenstrom Macroglobulinemia Market

The current treatment regimen for WM is based completely on improving symptoms, to cease the growth of the tumor and prevent further progression. The low-grade cases of WM are manageable with appropriate therapies but the advanced stage cases may create the threat of high morbidity and mortality. There are numerous treatment options available for the symptomatic patient pool of WM, such as Plasmapheresis, Chemotherapy, targeted therapy, and Stem cell transplantation/bone marrow transplantation.

Owing to the launch of upcoming therapies, the Waldenstrom Macroglobulinemia market dynamics is expected to change during the forecast period. Increasing awareness, the introduction of novel drugs, and changing lifestyles will also drive the Waldenstrom Macroglobulinemia market growth globally.

The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Waldenstrom Macroglobulinemia market size and share by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology.

The report gives a thorough detail of the Waldenstrom Macroglobulinemia market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. 

Waldenstrom Macroglobulinemia Epidemiology

The epidemiology section covers insights about the historical and current Waldenstrom Macroglobulinemia patient pool and forecasted trends for every seven major countries from 2017 to 2030. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.  

Waldenstrom Macroglobulinemia Epidemiology Subtype Segmentation

  • Total Prevalent Cases of Waldenstrom Macroglobulinemia

  • Total Incident Cases of Waldenstrom Macroglobulinemia

  • Gender-specific Cases of Waldenstrom Macroglobulinemia

  • Symptom-based Cases of Waldenstrom Macroglobulinemia

  • Diagnosed Cases of Waldenstrom Macroglobulinemia

  • Treatable-specific Cases of Waldenstrom Macroglobulinemia

Waldenstrom Macroglobulinemia Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Waldenstrom Macroglobulinemia market or expected to get launched in the market during the study period. The analysis covers Waldenstrom Macroglobulinemia market uptake by drugs; patient uptake by therapies; and sales of each drug.   

 Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The report also covers the Waldenstrom Macroglobulinemia Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the Waldenstrom Macroglobulinemia market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisition, and merger, licensing, patent details, and other information for Waldenstrom Macroglobulinemia emerging therapies.

The dynamics of the Waldenstrom Macroglobulinemia market is anticipated to change in the coming years owing to the expected launch of emerging therapies during the forecasted period. The current market of WM is dependent on the only approved drug Imbruvica (Ibrutinib), chemotherapy, and off-label use of other targeted therapies. The robust pipeline, emerging therapies, increasing awareness, and education and improvement in treatment are stimulating the growth market of WM. 

Waldenstrom Macroglobulinemia Companies:

  • AbbVie

  • BeiGene

  • Amgen

  • TG Therapeutics

  • Gilead Sciences)

  • Acerta Pharma BV

And many others.

Waldenstrom Macroglobulinemia Therapies covered in the report include:

  • Ibrutinib + Rituximab 

  • Venetoclax 

  • Umbralisib

  • BGB-3111 

  • Acalabrutinib

  • Zydelig 

  • Oprozomib

And many more.

Table of Content

1. Key Insights

2. Executive Summary 

3. Waldenstrom Macroglobulinemia Competitive Intelligence Analysis

4. Waldenstrom Macroglobulinemia Market Overview at a Glance

5. Waldenstrom Macroglobulinemia Disease Background and Overview

6. Waldenstrom Macroglobulinemia Patient Journey

7. Waldenstrom Macroglobulinemia Epidemiology and Patient Population

8. Waldenstrom Macroglobulinemia Treatment Algorithm, Current Treatment, and Medical Practices

9. Waldenstrom Macroglobulinemia Unmet Needs

10. Key Endpoints of Waldenstrom Macroglobulinemia Treatment

11. Waldenstrom Macroglobulinemia Marketed Products

12. Waldenstrom Macroglobulinemia Emerging Therapies

13. Waldenstrom Macroglobulinemia Seven Major Market Analysis

14. Attribute Analysis

15. Waldenstrom Macroglobulinemia Market Outlook (7 major markets)

16. Waldenstrom Macroglobulinemia Access and Reimbursement Overview

17. KOL Views on the Waldenstrom Macroglobulinemia Market.

18. Waldenstrom Macroglobulinemia Market Drivers

19. Waldenstrom Macroglobulinemia Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The table of contents is not exhaustive; the final content may vary. 

Get FREE sample copy at:

Latest Reports By DelveInsight
Waldenstrom Macroglobulinemia Pipeline Insights
Waldenstrom Macroglobulinemia Pipeline Insights, 2021 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Waldenstrom Macroglobulinemia market.

Healthcare Blogs –
Substance Use Disorder Treatment Market

The Substance Use Disorder treatment market possesses challenges in terms of diagnosis, accessibility, and affordability of care. Apart from these the lack of continuous support also creates a treatment gap and hinders the healthcare outcome for the affected person. To address the therapeutics need in the Substance Use Disorder market, some of the major pharmaceutical and biotech companies such as Omeros Corporation, KemPharm, InterveXion Therapeutics, MediciNova, and others are actively involved in the development of therapies. To read more, visit: Substance Use Disorder Treatment Market

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States